Literature DB >> 8677942

Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection.

J W Fang1, W W Shen, A Meager, J Y Lau.   

Abstract

To determine the status of the tumor necrosis factor-alpha (TNFalpha) system in the liver in chronic hepatitis B virus (HBV) infection, hepatic expression of TNFalpha, its two receptors (TNFR-A, TNFR-B), HLA class I antigens (HLA-I), and HBV core antigen (HBcAg) were studied by immunohistochemistry in 24 patients with chronic HBV infection. TNFalpha was detected exclusively in the infiltrating mononuclear cells (MNC) in 19 of 24 patients. The expression of TNFalpha in infiltrating MNC correlated with serum markers of HBV replication and liver histology. TNFR were detected in hepatocytes, sinusoidal cells, and infiltrating MNC. The expression of TNFR correlated with liver histology (p < 0.01) but had no bearing on viral replication. There was a parallel expression of TNFalpha and TNFR (p < 0.01). Hepatocytic expression of HLA-I was increased, and this was related to liver histology but not with TNF alpha nor TNFR. These data indicate that the TNFalpha system is activated in the liver in chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8677942

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

1.  Indirect regulation of CD4 T-cell responses by tumor necrosis factor receptors in an acute viral infection.

Authors:  Anju Singh; Marcel Wüthrich; Bruce Klein; M Suresh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

2.  Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys.

Authors:  Myong Ki Baeg; Seung Kew Yoon; Sun-Hye Ko; Kyung-Do Han; Hye Jin Choi; Si Hyun Bae; Jong Young Choi; Myung-Gyu Choi
Journal:  Hepatol Int       Date:  2016-02-05       Impact factor: 6.047

Review 3.  Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors:  Matthew B Carroll; Michael A Forgione
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

4.  Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.

Authors:  Yong Kwang Park; Jung Min Lee; Do Young Kim; Hye Young Chang; Ja Kyung Kim; Chun Kyon Lee; Jun Yong Park; Sang Hoon Ahn; Kwan Sik Lee; Kwang Hyub Han
Journal:  Dig Dis Sci       Date:  2009-10-15       Impact factor: 3.199

Review 5.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

6.  Tumor necrosis factor-alpha acts as a complete mitogen for primary rat hepatocytes.

Authors:  Heather A Iocca; Harriet C Isom
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 7.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 8.  TNFalpha blockade in human diseases: mechanisms and future directions.

Authors:  Maida Wong; David Ziring; Yael Korin; Sheetal Desai; Sungjin Kim; Jan Lin; David Gjertson; Jonathan Braun; Elaine Reed; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-03       Impact factor: 3.969

9.  Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports.

Authors:  Primal P Kaur; Virginia C Chan; Steven N Berney
Journal:  Clin Rheumatol       Date:  2008-06-03       Impact factor: 2.980

Review 10.  Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease.

Authors:  Mark A Feitelson; Helena M G P V Reis; N Lale Tufan; Bill Sun; Jingbo Pan; Zhaorui Lian
Journal:  Cancer Lett       Date:  2009-02-06       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.